MCID: ADR009
MIFTS: 39

Adrenal Cortex Disease malady

Categories: Endocrine diseases

Aliases & Classifications for Adrenal Cortex Disease

Aliases & Descriptions for Adrenal Cortex Disease:

Name: Adrenal Cortex Disease 12 14
Adrenal Cortex Diseases 42 69

Classifications:



External Ids:

Disease Ontology 12 DOID:3952
MeSH 42 D000303
SNOMED-CT 64 129636003
UMLS 69 C0001614

Summaries for Adrenal Cortex Disease

MalaCards based summary : Adrenal Cortex Disease, also known as adrenal cortex diseases, is related to primary pigmented nodular adrenocortical disease and burning mouth syndrome type 3. An important gene associated with Adrenal Cortex Disease is POMC (Proopiomelanocortin), and among its related pathways/superpathways are Corticotropin-releasing hormone signaling pathway and Glucocorticoid receptor regulatory network. The drugs Galantamine and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include adrenal cortex and cortex, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Adrenal Cortex Disease

Diseases related to Adrenal Cortex Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 105)
id Related Disease Score Top Affiliating Genes
1 primary pigmented nodular adrenocortical disease 10.8
2 burning mouth syndrome type 3 10.3 POMC SST
3 distal monosomy 14q 10.3 POMC REN
4 renal hypoplasia, bilateral 10.3 POMC SST
5 water-clear cell adenoma 10.3 POMC SST
6 spastic ataxia 3 10.3 CYP11B1 CYP11B2
7 vaginal adenoma 10.3 POMC SST
8 glossopharyngeal nerve neoplasm 10.3 POMC REN
9 hypogonadism mitral valve prolapse mental retardation 10.3 CYP11B2 POMC REN
10 jackson-weiss syndrome 10.3 CYP11B1 CYP11B2 POMC
11 benign peritoneal mesothelioma 10.2 CYP11B1 CYP11B2 POMC
12 endometrial mixed adenocarcinoma 10.2 POMC REN
13 breast secretory carcinoma 10.2 CRH POMC SST
14 traumatic glaucoma 10.2 CRH HSD11B2 POMC
15 second-degree atrioventricular block 10.2 CYP11B1 CYP11B2 POMC
16 ameloblastoma 10.2 CYP11B1 POMC PRKAR1A
17 early-onset parkinson disease 10.2 CRH POMC SST
18 keratosis 10.2 CRH NR3C1 POMC
19 smith-mccort dysplasia 2 10.2 NR3C2 REN
20 hereditary multiple exostoses 10.2 CRH NR3C1 POMC
21 lichen disease 10.2 CRH NR3C1 POMC
22 microphthalmia, isolated, with coloboma 7 10.2 CYP11B2 NR3C2 REN
23 hyperlipoproteinemia type iii 10.2 INS POMC
24 uterine ligament cancer 10.2 PRKAR1A SST
25 congenital tricuspid stenosis 10.2 POMC PRL
26 intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies 10.2 CYP11B1 CYP11B2 KCNJ5
27 prostate neuroendocrine neoplasm 10.2 HSD11B2 NR3C2 REN
28 loeffler endocarditis 10.2 CRH CYP11B1 POMC REN
29 intermittent squint 10.2 CRH POMC PRL
30 cerebral hemisphere lipoma 10.2 PRL SST
31 lymph node cancer 10.2 CRH NR3C1
32 adult i blood group with or without congenital cataract 10.2 CRH POMC PRL
33 clear cell acanthoma 10.1 CYP11B1 HSD11B2 POMC REN
34 acute gonococcal salpingitis 10.1 CRH POMC PRL
35 splenic tuberculosis 10.1 HSD11B2 NR3C1 NR3C2
36 african histoplasmosis 10.1 POMC PRL SST
37 extragonadal nonseminomatous germ cell tumor 10.1 POMC PRL SST
38 hypoglycemic coma 10.1 CRH INS NR3C1
39 pulmonary neuroendocrine tumor 10.1 POMC PRL SST
40 shaken baby syndrome 10.1 INS REN SST
41 glioma susceptibility 1 10.1 CYP11B1 CYP11B2 HSD11B2 PRKAR1A
42 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 10.1 CRH POMC PRL
43 paranasal sinus cancer, adult 10.1 INS SST
44 rheumatic encephalitis 10.1 POMC PRL SST
45 aorta angiosarcoma 10.1 HSD11B2 NR3C2 POMC REN
46 neurogenic arthropathy 10.1 INS POMC SST
47 posterior uveal melanoma 10.1 CYP11B1 INS POMC
48 critical limb ischemia 10.1 CYP11B2 NR3C2 REN
49 bile acid synthesis defect, congenital, 4 10.1 POMC PRL SST
50 image syndrome 10.1 INS KCNJ5

Graphical network of the top 20 diseases related to Adrenal Cortex Disease:



Diseases related to Adrenal Cortex Disease

Symptoms & Phenotypes for Adrenal Cortex Disease

MGI Mouse Phenotypes related to Adrenal Cortex Disease:

44 (show all 15)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.35 NR3C1 NR3C2 PDE11A POMC PRKAR1A PRL
2 homeostasis/metabolism MP:0005376 10.25 SST AIRE CRH CYP11B1 CYP11B2 HSD11B2
3 cardiovascular system MP:0005385 10.22 CYP11B1 CYP11B2 HSD11B2 INS KCNJ5 NR3C1
4 growth/size/body region MP:0005378 10.22 AIRE CRH CYP11B1 CYP11B2 INS NR3C1
5 cellular MP:0005384 10.16 AIRE CRH CYP11B1 HSD11B2 INS NR3C1
6 endocrine/exocrine gland MP:0005379 10.15 PRL AIRE CRH CYP11B1 CYP11B2 INS
7 hematopoietic system MP:0005397 10.11 CYP11B2 INS NR3C1 NR3C2 POMC PRKAR1A
8 immune system MP:0005387 10.1 AIRE CRH CYP11B2 INS NR3C1 POMC
9 adipose tissue MP:0005375 10.02 CRH CYP11B2 INS NR3C1 POMC PRKAR1A
10 nervous system MP:0003631 10 INS NR3C1 NR3C2 PDE11A POMC PRL
11 liver/biliary system MP:0005370 9.97 AIRE CRH CYP11B2 INS NR3C1 POMC
12 muscle MP:0005369 9.87 CYP11B1 HSD11B2 INS NR3C1 NR3C2 PRKAR1A
13 no phenotypic analysis MP:0003012 9.7 SST AIRE CRH HSD11B2 INS NR3C1
14 normal MP:0002873 9.56 AIRE CRH HSD11B2 INS NR3C1 PRKAR1A
15 renal/urinary system MP:0005367 9.28 CRH CYP11B1 CYP11B2 HSD11B2 INS NR3C1

Drugs & Therapeutics for Adrenal Cortex Disease

Drugs for Adrenal Cortex Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 597)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Galantamine Approved Phase 4 357-70-0 9651 908828, 9651
2
Benzocaine Approved Phase 4 1994-09-7, 94-09-7 2337
3
Nimodipine Approved Phase 4 66085-59-4 4497
4
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 2 79217-60-0, 59865-13-3 5284373 6435893
5
Daclizumab Approved, Investigational Phase 4 152923-56-3
6
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1 159351-69-6 6442177
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 22916-47-8 4189
8
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 53123-88-9 5284616 6436030 46835353
9
Glyburide Approved Phase 4 10238-21-8 3488
10
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
11
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 51-43-4 5816
12
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 5754 657311
13
Etomidate Approved Phase 4,Phase 1,Phase 2 33125-97-2 36339 667484
14
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 1 59467-70-8 4192
15
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 1 2078-54-8 4943
16
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
17
Alendronate Approved Phase 4,Phase 2 121268-17-5, 66376-36-1 2088
18
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3 113-45-1 4158
19
Fluoxetine Approved, Vet_approved Phase 4,Phase 2 54910-89-3 3386
20
Losartan Approved Phase 4 114798-26-4 3961
21
Cosyntropin Approved Phase 4,Phase 1 16960-16-0 16129617
22
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
23
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
24
Citalopram Approved Phase 4,Phase 2 59729-33-8 2771
25
Armodafinil Approved, Investigational Phase 4,Phase 2 112111-43-0
26
Modafinil Approved, Investigational Phase 4,Phase 2 68693-11-8 4236
27
Alprostadil Approved, Investigational Phase 4 745-65-3 149351
28
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
29
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
30
Norepinephrine Approved Phase 4,Early Phase 1 51-41-2 439260
31
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
32
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2 137-58-6 3676
33
Liraglutide Approved Phase 4,Phase 2 204656-20-2
34
Denosumab Approved Phase 4,Phase 3,Phase 2 615258-40-7
35
Teriparatide Approved, Investigational Phase 4,Phase 2,Phase 3 52232-67-4 16133850
36
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 5460373 44475014
37
Metformin Approved Phase 4 657-24-9 14219 4091
38
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
39
Levodopa Approved Phase 4,Phase 2 59-92-7 6047
40
Methyltestosterone Approved Phase 4,Phase 2 58-18-4 6010
41
Testosterone Approved, Investigational Phase 4,Phase 2 58-22-0 6013
42
Acetylcysteine Approved, Investigational Phase 4,Phase 1 616-91-1 12035
43
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
44
Ethanol Approved Phase 4,Phase 3,Phase 2 64-17-5 702
45
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
46
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
47
Carbidopa Approved Phase 4 28860-95-9 34359 38101
48
Zoledronic acid Approved Phase 4,Phase 3 118072-93-8 68740
49
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
50
Estradiol Approved, Investigational, Vet_approved Phase 4,Early Phase 1 50-28-2 5757 53477783

Interventional clinical trials:

(show top 50) (show all 1184)
id Name Status NCT ID Phase
1 Effect of Cognitive Intervention in Alzheimer's Disease (AD) on Functional Cortical Networks in fMRI Unknown status NCT01329601 Phase 4
2 Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®) Unknown status NCT00523666 Phase 4
3 Nimodipine for Treating Acute Massive Cerebral Infarction Unknown status NCT02248233 Phase 4
4 Tear Film Evaluation After Phacoemulsification Unknown status NCT02238015 Phase 4
5 Fibrosis in Renal Allografts Unknown status NCT00493194 Phase 4
6 Do Sulphonylureas Preserve Cortical Function During Hypoglycaemia? Unknown status NCT00472875 Phase 4
7 Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome Unknown status NCT02424695 Phase 4
8 Effect of Treatment With Stress-Doses Glucocorticoid in Patients With Acute Respiratory Distress Syndrome (ARDS) Unknown status NCT00773058 Phase 4
9 Effects of Etomidate on Postoperative Circadian Rhythm Changes of Salivary Cortisol in Children Unknown status NCT02013986 Phase 4
10 The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder Completed NCT00678574 Phase 4
11 Brain Imaging Study in Menopausal Women With and Without Major Depressive Disorder Completed NCT00626340 Phase 4
12 Angiotensin II Blockade for Chronic Allograft Nephropathy Completed NCT00067990 Phase 4
13 Revival of Stem Cells in Addison's Study Completed NCT01371526 Phase 4
14 A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder Completed NCT00206102 Phase 4
15 Effects of Paxil CR on Neural Circuits in Posttraumatic Stress Disorder (PTSD) Completed NCT00672776 Phase 4
16 Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms Completed NCT01919216 Phase 4
17 Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory Performance Completed NCT00711516 Phase 4
18 Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta Completed NCT01713231 Phase 4
19 Repository Corticotropin Injection To Treat Rheumatoid Arthritis Patients Who Have Failed Three Biologic Therapies. Completed NCT01966718 Phase 4
20 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients With Diabetic Nephropathy Completed NCT02628106 Phase 4
21 On the Impact of Bleeding on Two Strategies Osteosynthesis of Trochanteric Fractures Completed NCT01427036 Phase 4
22 Desmopressin Melt: Impact on Sleep and Daytime Functioning Completed NCT01645475 Phase 4
23 Repetitive Transcranial Stimulation (rTMS) in Post Stroke Dysphagia Completed NCT01081444 Phase 4
24 Economic Medical Evaluation of Treatment of the Neuropathic Pain Rebel by Cortical Stimulation Completed NCT00241566 Phase 4
25 A Study To Assess the Quality and Strength of Bone in Women Participants With Osteoporosis Taking Oral Ibandronate Versus Placebo Completed NCT00148915 Phase 4
26 A Study To Assess The Quality Of Bone In Patients Taking Oral Ibandronate Versus Placebo Completed NCT02948881 Phase 4
27 Adrenal Cortical Function and Vitamin A Deficiency in Sepsis Completed NCT03152474 Phase 4
28 Rosuvastatin Gel With 1:1 Mixture of Platelet-rich Fibrin and Bone Graft in Mandibular Degree II Furcation Defects Completed NCT02369250 Phase 4
29 HLA Sensitization Following Major Cortical Allograft Bone Procedures Completed NCT00160719 Phase 4
30 Quetiapine Induced Neuroplasticity in First-episode Schizophrenic Patients Completed NCT00554658 Phase 4
31 Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia Completed NCT00488163 Phase 4
32 Doxycycline In Lymphangioleiomyomatosis (LAM) Completed NCT00989742 Phase 4
33 Anesthetic Efficacy of Articaine and Lidocaine in Lower Molars With Irreversible Pulpits Completed NCT01912755 Phase 4
34 Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI Completed NCT01562678 Phase 4
35 RA Denosumab on Bone Microstructure Study Completed NCT01770106 Phase 4
36 Phase Out in Tinnitus Patients Completed NCT00833950 Phase 4
37 A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide Completed NCT00557310 Phase 4
38 The Forteo Alendronate Comparator Trial Completed NCT02416271 Phase 4
39 Teriparatide Treatment in Patients With Inherited Osteoporosis Completed NCT01360424 Phase 4
40 A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis Completed NCT00682643 Phase 4
41 Myo-inositol Versus D-chiro-inositol in the Treatment of Polycystic Ovary Syndrome and Insulin Resistance: Evaluation of Clinical, Metabolic, Endocrine and Ultrasound Parameters Completed NCT01514942 Phase 4
42 Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health Completed NCT00679939 Phase 4
43 Rapamycin In Angiomyolipomas In Patients With Tuberous Sclerosis Completed NCT01217125 Phase 4
44 Efficacy of Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) Treatment on Prefrontality in Patients With Generalized Anxiety Disorder (GAD) and Other Comorbidities Recruiting NCT01975480 Phase 4
45 Effect of Acute Hyperglycemia on Renal Tissue Oxygenation Recruiting NCT02346149 Phase 4
46 Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of Subcutaneous Tocilizumab in Rheumatoid Arthritis Recruiting NCT02765074 Phase 4
47 Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD Recruiting NCT02977299 Phase 4
48 Chronic Pain Risk Associated With Menstrual Period Pain Recruiting NCT02214550 Phase 4
49 Perioperative Mirror Therapy and Phantom Limb Pain Recruiting NCT02383979 Phase 4
50 Analgesic Effect of Non Invasive Stimulation : Comparison of rTMS and tDCS Efficacy Recruiting NCT01800136 Phase 4

Search NIH Clinical Center for Adrenal Cortex Disease

Cochrane evidence based reviews: adrenal cortex diseases

Genetic Tests for Adrenal Cortex Disease

Anatomical Context for Adrenal Cortex Disease

MalaCards organs/tissues related to Adrenal Cortex Disease:

39
Adrenal Cortex, Cortex

Publications for Adrenal Cortex Disease

Articles related to Adrenal Cortex Disease:

id Title Authors Year
1
Hypertension and adrenal cortex disease. A review of 100 autopsied cases. ( 5491407 )
1970

Variations for Adrenal Cortex Disease

Expression for Adrenal Cortex Disease

Search GEO for disease gene expression data for Adrenal Cortex Disease.

Pathways for Adrenal Cortex Disease

GO Terms for Adrenal Cortex Disease

Cellular components related to Adrenal Cortex Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 endosome lumen GO:0031904 8.62 INS PRL

Biological processes related to Adrenal Cortex Disease according to GeneCards Suite gene sharing:

(show all 15)
id Name GO ID Score Top Affiliating Genes
1 steroid metabolic process GO:0008202 9.7 CRH CYP11B1 CYP11B2
2 female pregnancy GO:0007565 9.69 CRH HSD11B2 PRL
3 regulation of blood pressure GO:0008217 9.63 CYP11B1 POMC REN
4 cellular response to hormone stimulus GO:0032870 9.58 CYP11B1 CYP11B2 PRL
5 sterol metabolic process GO:0016125 9.55 CYP11B1 CYP11B2
6 response to drug GO:0042493 9.55 CRH HSD11B2 PRL REN SST
7 response to immobilization stress GO:0035902 9.54 CRH REN
8 C21-steroid hormone biosynthetic process GO:0006700 9.49 CYP11B1 CYP11B2
9 parturition GO:0007567 9.48 CRH PRL
10 cellular response to potassium ion GO:0035865 9.43 CYP11B1 CYP11B2
11 hormone-mediated apoptotic signaling pathway GO:0008628 9.37 CRH SST
12 aldosterone biosynthetic process GO:0032342 9.32 CYP11B1 CYP11B2
13 cortisol biosynthetic process GO:0034651 9.26 CYP11B1 CYP11B2
14 regulation of blood volume by renal aldosterone GO:0002017 8.96 CYP11B2 HSD11B2
15 glucocorticoid biosynthetic process GO:0006704 8.8 CRH CYP11B1 HSD11B2

Molecular functions related to Adrenal Cortex Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 steroid binding GO:0005496 9.43 HSD11B2 NR3C1 NR3C2
2 cAMP binding GO:0030552 9.37 PDE11A PRKAR1A
3 insulin-like growth factor receptor binding GO:0005159 9.32 INS REN
4 corticosterone 18-monooxygenase activity GO:0047783 9.16 CYP11B1 CYP11B2
5 hormone activity GO:0005179 9.02 CRH INS POMC PRL SST
6 steroid 11-beta-monooxygenase activity GO:0004507 8.96 CYP11B1 CYP11B2

Sources for Adrenal Cortex Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....